Keywords: Hypertension, Telmisartan, Amlodipine, Valsartan, Novartis, Market, USA, Europe, Fixed-dose combinations
Fixed-dose combo of telmisartan/amlodipine “will become clinical gold standard for hypertension” in 2013
Article | 08 January 2010
A hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30% patient share according to surveyed US ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
